Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May;20(5):672-682.
doi: 10.1038/s41565-025-01877-5. Epub 2025 Mar 17.

The pathways for nanoparticle transport across tumour endothelium

Affiliations

The pathways for nanoparticle transport across tumour endothelium

Jamie L Y Wu et al. Nat Nanotechnol. 2025 May.

Abstract

The active transport and retention principle is an alternative mechanism to the enhanced permeability and retention effect for explaining nanoparticle tumour delivery. It postulates that nanoparticles actively transport across tumour endothelial cells instead of passively moving through gaps between these cells. How nanoparticles transport across tumour endothelial cells remains unknown. Here we show that nanoparticles cross tumour endothelial cells predominantly using the non-receptor-based macropinocytosis pathway. We discovered that tumour endothelial cell membrane ruffles capture circulating nanoparticles, internalize them in intracellular vesicles and release them into the tumour interstitium. Tumour endothelial cells have a higher membrane ruffle density than healthy endothelium, which may partially explain the elevated nanoparticle tumour accumulation. Receptor-based endocytosis pathways such as clathrin-mediated endocytosis contribute to nanoparticle transport to a lesser extent. Nanoparticle size determines the degree of contribution for each pathway. Elucidating the nanoparticle transport mechanism is crucial for developing strategies to control nanoparticle tumour delivery.

PubMed Disclaimer

Conflict of interest statement

Competing interests: J.M. does sponsored research for Merck. W.C.W.C. is a co-founder of Luna Nanotech and consults for Foresite Ventures, METiS Therapeutics, Cystic Fibrosis Foundation, Merck and Moderna. The other authors declare no competing interests.

References

    1. Hobbs, S. K. et al. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc. Natl Acad. Sci. USA 95, 4607–4612 (1998). - PubMed - PMC - DOI
    1. Peer, D. et al. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751–760 (2007). - PubMed - DOI
    1. He, H., Liu, L., Morin, E. E., Liu, M. & Schwendeman, A. Survey of clinical translation of cancer nanomedicines—lessons learned from successes and failures. Acc. Chem. Res. 52, 2445–2461 (2019). - PubMed - DOI
    1. Wilhelm, S. et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1, 16014 (2016). - DOI
    1. Sindhwani, S. et al. The entry of nanoparticles into solid tumours. Nat. Mater. 19, 566–575 (2020). - PubMed - DOI

LinkOut - more resources